 |
| ciprocin |
Creetinlne Clearance (mLlmin.) Dose
>50 (Oral); >30 (IV) See usual dose.
30—50 250—500mg/l2hrst
5—29 I 250—sOOmg/l8hrs)Oral); I 200—400mgIle.24hrs)IV)
Haemodtatysis or Perit000al dialysis 25Q — 500 mg!24 hours (after dialysis) Dosage In Hepatic Function Impairment: No dosage adjustment except In severe impairment.
IV Route:
Ciprocin® Vials should be diluted prior to administration and given by intravenous (IV) infusion over 60 minutes.
Preparation of IV Dose:
Prepare the IV dose by aseptically withdrawing the appropriate volume of concentrate from the vial. Dilute before use with a suitable IV infusion to a final concentration of
1 —2 mg/mL.
Admixture Compatlbfflty/Stabuity:
Stable up to 14 days under refrigeration or at room temperature (5° — 25° C) when diluted with 0.9% sodium chloride injection or 5% dextrose injection, sterile water for injection, 10% dextrose for injection, 5% dextrose and 0.225% sodium chloride for injection, 5% dextrose and 0.45% sodium chloride for injection. If a V — type IV infusion set or a piggyback method is used, temporarily discontinue the administration of any other solution during the Ciprocin® infusion.
Ciprocin® is incompatible with amoxicillin, mezlocitlin, flucloxacillin, pefloxacin, heparin sodium, frusemide, aminophytline and lecicoplanin. Drug Interactions: -As with other fluoroquinolones, concurrent use of aluminium, magnesium hydroxide antacids, iron and zinc salts or sucralt ate is better avoided.
(Aluminium, magnesium, or iron preparations are not given within 4 hours).
(Sucrslfste can be given 6hours before Ciprocin®). -Concurrent administration of ciproftoxacin with caffeine, theophyuine, daily products or enteral feedings is better avoided.
-Ciprocin® may increase cyclosporine toxicity.
-Oploid premedication should not be used if Ciprocin® is given for surgical infection proptlylaxls.
>50 (Oral); >30 (IV) See usual dose.
30—50 250—500mg/l2hrst
5—29 I 250—sOOmg/l8hrs)Oral); I 200—400mgIle.24hrs)IV)
Haemodtatysis or Perit000al dialysis 25Q — 500 mg!24 hours (after dialysis) Dosage In Hepatic Function Impairment: No dosage adjustment except In severe impairment.
IV Route:
Ciprocin® Vials should be diluted prior to administration and given by intravenous (IV) infusion over 60 minutes.
Preparation of IV Dose:
Prepare the IV dose by aseptically withdrawing the appropriate volume of concentrate from the vial. Dilute before use with a suitable IV infusion to a final concentration of
1 —2 mg/mL.
Admixture Compatlbfflty/Stabuity:
Stable up to 14 days under refrigeration or at room temperature (5° — 25° C) when diluted with 0.9% sodium chloride injection or 5% dextrose injection, sterile water for injection, 10% dextrose for injection, 5% dextrose and 0.225% sodium chloride for injection, 5% dextrose and 0.45% sodium chloride for injection. If a V — type IV infusion set or a piggyback method is used, temporarily discontinue the administration of any other solution during the Ciprocin® infusion.
Ciprocin® is incompatible with amoxicillin, mezlocitlin, flucloxacillin, pefloxacin, heparin sodium, frusemide, aminophytline and lecicoplanin. Drug Interactions: -As with other fluoroquinolones, concurrent use of aluminium, magnesium hydroxide antacids, iron and zinc salts or sucralt ate is better avoided.
(Aluminium, magnesium, or iron preparations are not given within 4 hours).
(Sucrslfste can be given 6hours before Ciprocin®). -Concurrent administration of ciproftoxacin with caffeine, theophyuine, daily products or enteral feedings is better avoided.
-Ciprocin® may increase cyclosporine toxicity.
-Oploid premedication should not be used if Ciprocin® is given for surgical infection proptlylaxls.
Contraindications: As with other quinolones, Ciprocin® is contraindicated in hypersensitivity to quinolones, tendinitis or tendon rupture associated with quino)one use, pregnant women or breast-feeding mothers, children and adolescents less than l8yearsof age. Side Effects: Ciprocin® is generally well-tolerated. Most reactions are mild to moderate. As with other quinolones, gastrointestinal disturbances e.g. nausea, vomiting, diarrhea, abdominal pain, dyspepsia, pseudomembraneous colitis (rarely) central nervous system disturbances e.g. headache, dizziness, restlessness, tremor, drowsiness, insomnia, visual disturbances; skin reactions e.g. photosensitivity, rash, pruritus; vaginitis; transient increases in serum crestinine, blood urea nitrogen, crystalluria; elevated liver enzymes; eosinophilia, leucopenia, thrombocytopenia; myalgia, tendinitis or tendon rupture; tachycardia, edema may occasionally occur. Pain and irritation may occur at the site of injection accompanied rarely by phlebitis or thrombophlebitis. How Supplied: Clprocin® 250mg Film-Coated Tablets: Box of 1 blister of 10 tablets.
Clprocin® 500 mg Film-Coated Tablets: Box of 1 blister of 10 tablets.
Ciprocin® 750 mg Film-Coated Tablets: Box of 2 blisters of 5 tablets
each.
Clprocin® 200 mg Vials: Box of 1 vial of 20 ml. Storage: Tablets stored at temp. not exceeding 30° C.
Vials stored at temp. 15° -30° C.
1) Is aMethceet.
•Medicanrent ala prOdactwtrich affects your health, and So consumption consary to instructions Is dangemso fur you.
•Follow sS50y the doctot’s prescnptioe, sot method of use, and the instruchons of the phamacet who surId Ste meetcernent.
.me doctor sod the phannaost are experts fu medtore, So benefits sod tlskst .00 not brtetrupt the period xl treasnent prescubed by yourself.
•Do not repeat lbs same prescription without consahing poor doctor.
•Ke€p medirines out of the reach of chddrer.
Clprocin® 500 mg Film-Coated Tablets: Box of 1 blister of 10 tablets.
Ciprocin® 750 mg Film-Coated Tablets: Box of 2 blisters of 5 tablets
each.
Clprocin® 200 mg Vials: Box of 1 vial of 20 ml. Storage: Tablets stored at temp. not exceeding 30° C.
Vials stored at temp. 15° -30° C.
1) Is aMethceet.
•Medicanrent ala prOdactwtrich affects your health, and So consumption consary to instructions Is dangemso fur you.
•Follow sS50y the doctot’s prescnptioe, sot method of use, and the instruchons of the phamacet who surId Ste meetcernent.
.me doctor sod the phannaost are experts fu medtore, So benefits sod tlskst .00 not brtetrupt the period xl treasnent prescubed by yourself.
•Do not repeat lbs same prescription without consahing poor doctor.
•Ke€p medirines out of the reach of chddrer.
Precautions: -Ciprocin® should be cautiously used in patients with known or suspected central nervous system disorders, or other factors predisposing to seizures; impaired renal or hepatic function; G6PD deficiency; myasthenia gravis; elderly.
-Exposure to strong sunlight or sunlamps should be avoided.
-An adequate fluid intake should be maintained durir treatment with Ciprocin® and excessive alkalinity of the urine avoided because of risk of crystalluris.
-Tendon damage may occur rarely with fluoroquinones and treatment should be discontinued if patients experience tendon pain, inflammation, or rupture; subsequent use of fluoroquinolones is contraindicated.
-The ability to drive or operate machinery may be impaired by Ciprocin®, especially when alcohol is also taken.
-1-lyper- or hypoglycemia, usually in diabetic patients receiving concomitant oral hypoglycemic agents or insulin, may occur with quinolones.
-Exposure to strong sunlight or sunlamps should be avoided.
-An adequate fluid intake should be maintained durir treatment with Ciprocin® and excessive alkalinity of the urine avoided because of risk of crystalluris.
-Tendon damage may occur rarely with fluoroquinones and treatment should be discontinued if patients experience tendon pain, inflammation, or rupture; subsequent use of fluoroquinolones is contraindicated.
-The ability to drive or operate machinery may be impaired by Ciprocin®, especially when alcohol is also taken.
-1-lyper- or hypoglycemia, usually in diabetic patients receiving concomitant oral hypoglycemic agents or insulin, may occur with quinolones.
PMS Slack C.16fl6CM 56 g/m2 116 100 PAN 001 EEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE500EEEESEEEEEEEEEEESS!EEEEEEEEEEEEEEEEEEEE EGYPTIAN INT. PHARMACEUTICAL INDUSTRIES CO. E. I. P. i. Co. 10th OF RAMADAN CITY , AREA Bi RO.BOX 149 TENTH, EGYPT
No comments:
Post a Comment